JPMorgan Chase & Co. Sells 94,465 Shares of Arcellx, Inc. $ACLX

JPMorgan Chase & Co. lessened its holdings in shares of Arcellx, Inc. (NASDAQ:ACLX) by 9.7% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 882,503 shares of the company’s stock after selling 94,465 shares during the period. JPMorgan Chase & Co. owned approximately 1.59% of Arcellx worth $72,453,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in ACLX. Decheng Capital LLC raised its holdings in Arcellx by 995.2% in the 2nd quarter. Decheng Capital LLC now owns 547,609 shares of the company’s stock valued at $36,060,000 after acquiring an additional 497,609 shares in the last quarter. American Century Companies Inc. grew its holdings in Arcellx by 694.3% during the 2nd quarter. American Century Companies Inc. now owns 431,466 shares of the company’s stock worth $28,412,000 after acquiring an additional 377,145 shares during the last quarter. Vestal Point Capital LP raised its position in Arcellx by 15.2% in the 2nd quarter. Vestal Point Capital LP now owns 2,750,000 shares of the company’s stock worth $181,088,000 after purchasing an additional 362,280 shares during the last quarter. Bank of America Corp DE increased its position in Arcellx by 60.3% in the second quarter. Bank of America Corp DE now owns 262,355 shares of the company’s stock worth $17,276,000 after purchasing an additional 98,685 shares during the period. Finally, Marshall Wace LLP raised its stake in shares of Arcellx by 626.0% during the second quarter. Marshall Wace LLP now owns 111,808 shares of the company’s stock worth $7,363,000 after buying an additional 96,408 shares during the last quarter. Institutional investors own 96.03% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Leerink Partners restated a “market perform” rating and set a $115.00 target price on shares of Arcellx in a report on Tuesday. Wells Fargo & Company downgraded Arcellx from an “overweight” rating to an “equal weight” rating and set a $115.00 price objective on the stock. in a research note on Monday. Truist Financial set a $120.00 price target on Arcellx in a report on Monday. HC Wainwright cut Arcellx from a “buy” rating to a “neutral” rating and set a $115.00 price objective on the stock. in a report on Monday. Finally, Canaccord Genuity Group set a $115.00 target price on shares of Arcellx in a report on Monday. Two equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $111.64.

Arcellx Trading Down 0.0%

Arcellx stock opened at $113.71 on Wednesday. Arcellx, Inc. has a 1-year low of $47.86 and a 1-year high of $114.26. The company has a fifty day simple moving average of $68.84 and a 200 day simple moving average of $75.38. The company has a market cap of $6.57 billion, a P/E ratio of -28.93 and a beta of 0.36.

More Arcellx News

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Gilead Sciences agreed to acquire Arcellx for $115.00 per share in cash plus one contingent value right worth $5.00 if milestones are met, implying up to ~$7.8 billion — a takeover premium that drove a large rally. Gilead acquisition release
• Positive Sentiment: Market reaction: the deal triggered a premarket surge (roughly 75–80% intraday move at announcement) and sharply elevated trading volumes as the market re‑priced ACLX to reflect the cash consideration. Reuters coverage
• Neutral Sentiment: HC Wainwright updated FY2030 EPS expectations materially (analyst projects $4.95/sh) but kept a “Neutral” rating and $115 price objective — effectively aligned with the deal price and not implying incremental upside beyond the offer. MarketBeat report
• Negative Sentiment: Multiple brokerages downgraded ACLX to “hold”/”equal weight” (Truist, Baird, Canaccord, Needham, Wells Fargo, Citigroup), signaling limited upside above the deal price and reducing buy‑side conviction. Example coverage: Truist/Benzinga. Benzinga downgrades roundup
• Negative Sentiment: Several law firms (Kahn Swick & Foti, Halper Sadeh, Ademi, Monteverde) announced investigations into whether the $115 + $5 CVR consideration is fair — potential litigation could seek a higher price, delay closing or increase transaction risk/uncertainty. KSF investor alert

Insider Buying and Selling

In other Arcellx news, insider Christopher Heery sold 7,437 shares of the business’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $65.51, for a total transaction of $487,197.87. Following the transaction, the insider owned 29,631 shares of the company’s stock, valued at $1,941,126.81. The trade was a 20.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 19,450 shares of company stock worth $1,283,477 over the last ninety days. Corporate insiders own 8.35% of the company’s stock.

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.